Skip to main content

Table 2 HbA1c levels of patients with T2DM at 3, 6, and 12 months after MSCs therapy

From: Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis

Follow-up (months) Test for heterogeneity Analysis model Test for overall effect WMD or SMD 95% CI
I2 (%) P Z P
3 87 0.006 Random 0.89 0.37 −0.60 (−1.92, 0.72)
6 85 <0.0001 Random 2.60 0.009 −1.30 (2.27, −0.32)
12 66 0.09 Random 1.72 0.09 −0.75 (−1.60, 0.11)
  1. Abbreviations: HbA1c glycated hemoglobin, T2DM type 2 diabetes, MSCs mesenchymal stem cells, WMD weighted mean difference, SMD standard mean difference